Home > Healthcare > Medical Devices > Diagnostic Devices > Point-of-Care Glucose Testing Market

Point-of-Care Glucose Testing Market Share

Report ID: GMI11241
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Point-of-Care Glucose Testing Market Share

The point-of-care (POC) glucose testing industry is characterized by intense competition, with major global companies and smaller to medium-sized firms vying for market leadership. Key strategies for maintaining a competitive edge include the regular introduction of innovative technologies and products. Leading industry players drive innovation through significant investments in research and development.

Furthermore, strategic partnerships, acquisitions, and mergers are crucial for consolidating market positions and expanding international reach, enabling companies to enhance their market presence and leverage new opportunities. Smaller players are focusing on specific niches or bringing innovative approaches to POC testing. These companies often target underserved areas or specific medical conditions, creating competitive pressure on established players.

Point-of-Care Glucose Testing Market Companies

Some of the eminent market participants operating in the point-of-care glucose testing industry include:

Abbott Laboratories
ARKRAY, Inc.
ACON Laboratories, Inc.
B. Braun Melsungen AG
Dexcom, Inc.
EKF Diagnostics Holdings plc
F. Hoffmann-La Roche Ltd.
Medtronic plc
Nipro Corporation
Nova Biomedical Corporation
PHC Holdings
Prodigy Diabetes Care, LLC.
Platinum Equity Advisors, LLC.
Sanofi
Sinocare

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The point-of-care glucose testing market was valued at USD 3.4 billion in 2023 and will witness a 4.7% CAGR between 2024 and 2032 driven by the rising incidence of diabetes.

The test strips segment in the point-of-care glucose testing industry will attain USD 2.3 billion by 2032, due to their high accuracy and precision in glucose measurement.

U.S. point-of-care glucose testing market is expected to surpass USD 1.9 billion by 2032, owing to the highest diabetes prevalence rates, along with a well-established healthcare infrastructure that supports the widespread use of advanced medical technologies.

Abbott Laboratories, ARKRAY, Inc., ACON Laboratories, Inc., B. Braun Melsungen AG, and Dexcom, Inc., among others.